Abstract
Recently, we identified recurrent gene fusions involving the 5′ untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes ERG, ETV1 or ETV4 in most prostate cancers1,2. Whereas TMPRSS2–ERG fusions are predominant, fewer TMPRSS2–ETV1 cases have been identified than expected on the basis of the frequency of high (outlier) expression of ETV1 (refs 3–13). Here we explore the mechanism of ETV1 outlier expression in human prostate tumours and prostate cancer cell lines. We identified previously unknown 5′ fusion partners in prostate tumours with ETV1 outlier expression, including untranslated regions from a prostate-specific androgen-induced gene (SLC45A3) and an endogenous retroviral element (HERV-K_22q11.23), a prostate-specific androgen-repressed gene (C15orf21), and a strongly expressed housekeeping gene (HNRPA2B1). To study aberrant activation of ETV1, we identified two prostate cancer cell lines, LNCaP and MDA-PCa 2B, that had ETV1 outlier expression. Through distinct mechanisms, the entire ETV1 locus (7p21) is rearranged to a 1.5-megabase prostate-specific region at 14q13.3–14q21.1 in both LNCaP cells (cryptic insertion) and MDA-PCa 2B cells (balanced translocation). Because the common factor of these rearrangements is aberrant ETV1 overexpression, we recapitulated this event in vitro and in vivo, demonstrating that ETV1 overexpression in benign prostate cells and in the mouse prostate confers neoplastic phenotypes. Identification of distinct classes of ETS gene rearrangements demonstrates that dormant oncogenes can be activated in prostate cancer by juxtaposition to tissue-specific or ubiquitously active genomic loci. Subversion of active genomic regulatory elements may serve as a more generalized mechanism for carcinoma development. Furthermore, the identification of androgen-repressed and insensitive 5′ fusion partners may have implications for the anti-androgen treatment of advanced prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
08 October 2007
The original publication of this paper had the incorrect name 'Presner' in the Acknowledgements. This was corrected to 'Prenser' on 8 Oct 2007
References
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005)
Tomlins, S. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396–3400 (2006)
Cerveira, N. et al. TMPRSS2–ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8, 826–832 (2006)
Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M. & Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913–923 (2004)
Hermans, K. G. et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66, 10658–10663 (2006)
Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811–816 (2004)
Mehra, R. et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 6, 1177–1187 (2007)
Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337–8341 (2006)
Soller, M. J. et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosom. Cancer 45, 717–719 (2006)
Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nature Genet. 39, 41–51 (2007)
Winnes, M., Lissbrant, E., Damber, J. E. & Stenman, G. Molecular genetic analyses of the TMPRSS2–ERG and TMPRSS2–ETV1 gene fusions in 50 cases of prostate cancer. Oncol. Rep. 17, 1033–1036 (2007)
Yoshimoto, M. et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8, 465–469 (2006)
Yu, Y. P. et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790–2799 (2004)
Mitelman, F., Johansson, B. & Mertens, F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nature Genet. 36, 331–334 (2004)
Rowley, J. D. Chromosome translocations: dangerous liaisons revisited. Nature Rev. Cancer 1, 245–250 (2001)
Lin, B. et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180–4184 (1999)
Mertz, K. D. et al. Molecular characterization of the TMPRSS2–ERG gene fusion in the NCI-H660 prostate cancer cell line—a new perspective for an old model. Neoplasia 9, 200–206 (2007)
Rabbitts, T. H. Chromosomal translocations in human cancer. Nature 372, 143–149 (1994)
Demichelis, F. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene advance online publication, doi: 10.1038/sj.onc.1210237 (22 January 2007)
van Bokhoven, A. et al. Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate 57, 226–244 (2003)
Cai, C. et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol. Endocrinol. advance online publication, doi: 10.1210/me.2006-0480 (15 May 2007)
Rhodes, D. R. et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9, 443–454 (2007)
Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223–238 (2003)
Shappell, S. B. et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 64, 2270–2305 (2004)
Suzukawa, K. et al. Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 84, 2681–2688 (1994)
Wieser, R. Rearrangements of chromosome band 3q21 in myeloid leukemia. Leuk. Lymphoma 43, 59–65 (2002)
Rhodes, D. R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166–180 (2007)
Beheshti, B., Karaskova, J., Park, P. C., Squire, J. A. & Beatty, B. G. Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by sequential giemsa banding and spectral karyotyping. Mol. Diagn. 5, 23–32 (2000)
Rubin, M. A. et al. Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 6, 1038–1045 (2000)
Korenchuk, S. et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 15, 163–168 (2001)
Vandesompele, J. et al. Accurate normalization of real-time quantitative RT–PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (2002)
Specht, K. et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am. J. Pathol. 158, 419–429 (2001)
Stauffer, Y., Theiler, G., Sperisen, P., Lebedev, Y. & Jongeneel, C. V. Digital expression profiles of human endogenous retroviral families in normal and cancerous tissues. Cancer Immun. 4, 2 (2004)
Wiemels, J. L. & Greaves, M. Structure and possible mechanisms of TEL–AML1 gene fusions in childhood acute lymphoblastic leukemia. Cancer Res. 59, 4075–4082 (1999)
Acknowledgements
We thank D. Rhodes, S. Kalyana-Sundaram and T. Barrette for support of the OCM, L. Smith for cytogenetics assistance, E. Keller and J. Macoska for prostate cancer cell lines, J. Moran for discussions regarding endogenous retroviral elements, J. Prensner for technical assistance, and R. Craig and L. Stoolman for the FACS analysis. We thank the UM Transgenic Animal Model Core for generating transgenic mice and the UM Vector core for virus generation. This work was supported in part by Department of Defense (to R.M., A.M.C. and S.V.), the National Institutes of Health (to K.J.P., A.M.C., R.B.S., K.J.P. and A.M.C.), the Early Detection Research Network (to A.M.C.), the Prostate Cancer Foundation (to A.M.C.), and Gen-Probe Incorporated (to A.M.C.). A.M.C. is supported by a Clinical Translational Research Award from the Burroughs Wellcome Foundation. S.A.T. is supported by a Rackham Predoctoral Fellowship. K.J.P. is supported as an American Cancer Society Clinical Research Professor. S.A.T. is a Fellow of the Medical Scientist Training Program.
The primary microarray data have been deposited in NCBI’s Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) under the GEO series accession numbers GSE7701 and GSE7702. Sequences of the ETV1 fusion transcript junctions identified by RACE have been deposited in GenBank under accession numbers EF632109–EF632112.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The University of Michigan has filed for a patent on the detection of gene fusions in prostate cancer, on which S.A.T., R.M., M.A.R. and A.M.C. are co-inventors. The diagnostic field of use has been licensed to GenProbe Inc. A.M.C. also has a sponsored research agreement with GenProbe; however, GenProbe has had no role in the design or experimentation of this study, nor has it participated in the writing of the manuscript. Oncomine and the OCM are freely available to the academic community. The commerical rights to Oncomine and OCM have been licensed to Compendia Bioscience, which A.M.C. cofounded.
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1-16 with Legends, Supplementary Tables 1-5, Supplementary Discussion and additional references. (PDF 3607 kb)
Rights and permissions
About this article
Cite this article
Tomlins, S., Laxman, B., Dhanasekaran, S. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595–599 (2007). https://doi.org/10.1038/nature06024
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nature06024
This article is cited by
-
HERVK-mediated regulation of neighboring genes: implications for breast cancer prognosis
Retrovirology (2024)
-
LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy
Cell Death & Disease (2024)
-
Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer
BMC Cancer (2023)
-
HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET
Journal of Experimental & Clinical Cancer Research (2022)
-
PGC1 alpha coactivates ERG fusion to drive antioxidant target genes under metabolic stress
Communications Biology (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.